IntelliCell Biosciences Announces That It Is Collaborating With the Global Alliance for Innovation in Neuroscience, Inc. (GAI...
March 19 2014 - 9:30AM
Marketwired
IntelliCell Biosciences Announces That It Is Collaborating With the
Global Alliance for Innovation in Neuroscience, Inc. (GAIN) for
Autism, Dementia and Brain Trauma
NEW YORK, NY--(Marketwired - Mar 19, 2014) - IntelliCell
Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous vascular
cells (SVCs) derived from the blood vessels found in adipose
tissue, announced today that it will be entering into a
collaboration with the Global Alliance for Innovation in
Neuroscience, Inc. (GAIN) to use its unique approach to the harvest
and use of autologous adipose derived mesenchymal stem cells for
clinical neuroscience applications including autism, dementia and
brain trauma.
GAIN, a translational neuroscience research organization,
designs and develops innovative neuroimaging technologies and
computer analyses to assess and treat a variety of neuropsychiatric
disorders. GAIN has extensive experience in the imaging and
treatment of autism, dementia, brain trauma and other neurological
disorders.
IntelliCell BioSciences and GAIN are developing joint protocols
with initial efforts focusing on the assessment and treatment of
children and adults with Autism, Alzheimer's Dementia, and
returning warfighters with blast induced traumatic brain injury.
Dr. Sandlin Lowe of the Amen Clinic will lead the studies and
treatment of Autism and Alzheimer's disease using Intellicell's
patented ultrasonic technology.
IntelliCell's Chief Executive Officer, Dr. Steven Victor,
remarked, "This is a tremendously moving moment for IntelliCell to
work with Dr. Lowe and GAIN on viable treatments for Autism, a
disease that continues to grow in our society with unmet
clinical needs. We believe that the Intellicell's Stromal
Vascular Fraction Cells will offer adults and children with autism
a significant improvement in their quality of life. IntelliCell's
cellular therapy has also been used to successfully enhance the
life of a veteran who had sustained a traumatic brain injury while
on duty in Iraq. We believe that the stromal vascular fraction
cells have the potential to revolutionize the treatment of
Alzheimer's disease as well. We at IntelliCell are excited to
have this opportunity to work with the distinguished
neuroscientist, Dr Lowe."
According to Sandlin Lowe, MD, Co-Founder and Director of GAIN
and Consulting Clinician to the Amen Clinics New York, "Dr.
Victor's approach to stem cell treatments is
revolutionary. The IntelliCell BioSciences / GAIN
collaboration will expand the use of autologous mesenchymal stem
cells derived by sonification of the stromal vascular fraction of
adipose tissue for many neuropsychiatric conditions including
autism, dementia and brain injury.
"We at GAIN look forward to an exciting and fruitful
collaboration with IntelliCell BioSciences as together we pioneer
new methods in translational neuroscience for the imaging and
treatment of autism, Alzheimer's dementia, and brain blast
injuries," says Dr. Lowe.
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell BioSciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. IntelliCell will
also be seeking to develop technology-licensing agreements with
technology developers, universities, and international business
entities.
About Dr. Sandlin Lowe Dr. Lowe specializes in the treatment for
cognitive decline including dementia, traumatic brain injury,
Autism and other neurodevelopmental disorders.
Dr. Sandlin Lowe left the family farm in Coosa County, Alabama
to study Anthropology and later obtain his MD degree from Tulane
University in New Orleans by 1987. He was on the Faculty of the New
York University School of Medicine where he holds appointments in
both the Department of Psychiatry and the Department of Physiology
and Neuroscience. He is Consulting Neuropsychiatrist to the NYU
School of Medicine Brain Research Laboratories and Collaborating
Psychiatrist at the NYU Langone Center for Neuromagnetism. After 18
years of service and research at Bellevue Hospital Center (for
which he was honored with a Congressional Award), Dr. Lowe has
become the Chief of Psychiatry Assessment Services at the NYU -
Woodhull Medical and Mental Health Center, an affiliate institution
of the NYU Langone Medical Center and the New York University
School of Medicine.
Dr. Lowe is an expert in Translational Clinical Neuroscience and
Therapeutics. He is co-founder and Director of the Global Alliance
for Innovation in Neuroscience, Inc. (GAIN) along with the GAIN
Labs and GAIN Health. Dr. Lowe has created new paradigms for the
conceptualization, evaluation and treatment of patients with
neuropsychiatric conditions. The theoretical basis for this work is
founded upon his research with Dr. Rodolfo Llinas and Dr. E. Roy
John, two of the Fathers of modern day neuroscience.
In the past few years, for personal reasons, Dr. Lowe's efforts
have been directed towards autism spectrum disorders. He has
special interests in abnormal neural dynamic states, particularly
thalamocortical dysrhythmias, and how they manifest as major
pathophysiological mechanisms in neurodevelopmental disorders,
traumatic brain injuries, cognitive impairment/decline and
dementia. He now is specifically engaged in the search for the
etiologies of these dysrhythmias and treatments for them. Currently
Dr. Lowe and his colleagues are at work combining small molecules,
biologicals, and cellular and regenerative medicine therapeutics
with transcranial magnetic stimulation (rTMS) and other applied
field energy methods in the design of new treatment protocols for
autism, acquired brain injuries, and conditions of cognitive
impairment/decline and dementia.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell BioSciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308